Review article · 2018 · Open access
The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
Frontiers in Immunology, 9, 2052 · Published 11 September 2018 · DOI 10.3389/fimmu.2018.02052
In brief
“The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road” is a 2018 review article by Cleo Goyvaerts and Karine Breckpot, published in Frontiers in Immunology. OpenAlex counts 33 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 33
- Most cited in
- 2023 (7)
- Field-weighted impact
- 0.35
- References
- 192
- Authors
- 2
Abstract
Dendritic cells (DCs) are recognized as highly potent antigen-presenting cells that are able to stimulate cytotoxic T lymphocyte (CTL) responses with antitumor activity. Consequently, DCs have been explored as cellular vaccines in cancer immunotherapy. To that end, DCs are modified with tumor antigens to enable presentation of antigen-derived peptides to CTLs. In this review we discuss the use of viral vectors for in situ modification of DCs, focusing on their clinical applications as anticancer vaccines. Among the viral vectors discussed are those derived from viruses belonging to the families of the Poxviridae, Adenoviridae, Retroviridae, Togaviridae, Paramyxoviridae and Rhabdoviridae. We will further shed light on how the combination of viral vector-based vaccination with T-cell supporting strategies will bring this strategy to the next level.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Goyvaerts, C., & Breckpot, K. (2018). The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road. Frontiers in Immunology, 9, 2052. https://doi.org/10.3389/fimmu.2018.02052
MLA 9
Goyvaerts, Cleo, and Karine Breckpot. “The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road.” Frontiers in Immunology, vol. 9, 2018, p. 2052. https://doi.org/10.3389/fimmu.2018.02052.
Chicago
Goyvaerts, Cleo and Karine Breckpot. 2018. “The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road.” Frontiers in Immunology 9: 2052. https://doi.org/10.3389/fimmu.2018.02052.
Harvard
Goyvaerts, C. and Breckpot, K. (2018) ‘The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road’, Frontiers in Immunology, 9, p. 2052. doi:10.3389/fimmu.2018.02052.
IEEE
C. Goyvaerts and K. Breckpot, “The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road,” Frontiers in Immunology, vol. 9, p. 2052, 2018, doi: 10.3389/fimmu.2018.02052.
BibTeX
@article{goyvaerts2018journey,
title = {{The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road}},
author = {Goyvaerts, Cleo and Breckpot, Karine},
journal = {Frontiers in Immunology},
year = {2018},
volume = {9},
pages = {2052},
doi = {10.3389/fimmu.2018.02052},
url = {https://doi.org/10.3389/fimmu.2018.02052}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 1 | |
| 2019 | 4 | |
| 2020 | 6 | |
| 2021 | 4 | |
| 2022 | 2 | |
| 2023 | 7 | |
| 2024 | 6 | |
| 2025 | 3 |
Its field-weighted citation impact is 0.35: it has been cited 0.35 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- dendritic cells
- viral vector engineering
- cancer immunotherapy
- cellular vaccine
- antigen presentation
- cytotoxic T lymphocytes
- poxvirus vectors
- adenoviral vector
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Goyvaerts, C., & Breckpot, K. (2018). The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road. Frontiers in Immunology, 9, 2052. https://doi.org/10.3389/fimmu.2018.02052
How many times has this paper been cited?
33 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Cleo Goyvaerts, Karine Breckpot.
What is the DOI of this paper?
10.3389/fimmu.2018.02052, permanently at https://doi.org/10.3389/fimmu.2018.02052. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.